Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for chemo- and radioresistant non-Hodgkin's lymphoma cells

被引：0
|
作者：
Roscher, M. [1 ]
Hormann, I. [1 ]
Moreno, J. [2 ]
Leib, O. [2 ]
Marx, S. [2 ]
Miltner, E. [1 ]
Friesen, C. [1 ]
机构：
[1] Univ Ulm, Inst Legal Med, D-89069 Ulm, Germany
[2] Isotope Technol Garching GmbH ITG, Munich, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [31] Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).
    Meredith, R
    Shen, S
    Breitz, H
    Fisher, D
    Goris, M
    Knox, S
    Hankins, J
    Vose, J
    Picozzi, V
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 116P - 117P
  • [32] Alpha-radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using 213Bi-labelled anti-CD19-and anti-CD20-CHX-A"-DTPA conjugates.
    Heeger, S
    Moldenhauer, G
    Egerer, G
    Wesch, H
    Martin, S
    Nikula, T
    Apostolidis, C
    Brechbiel, MW
    Ho, AD
    Haas, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 225 : U261 - U261
  • [33] Anti-CD20 therapy for older patients with B-cell non-Hodgkin lymphoma in the context of epidemic normalization
    Zhang, Dongdong
    Xu, Shuangnian
    ASIAN JOURNAL OF SURGERY, 2024, 47 (07) : 3290 - 3292
  • [34] A pilot study of anti-CD20 MoAB rituximab in aids-associated non-Hodgkin's lymphoma.
    Barrett, JC
    Linn, CA
    Arani, RB
    Rosenberg, J
    Saleh, MN
    BLOOD, 1999, 94 (10) : 258B - 258B
  • [35] GEMCITABINE, OXALIPLATIN, AND ANTI-CD20 THERAPY IS SAFE AND EFFECTIVE IN CHILDREN AND YOUNG ADULTS WITH NON-HODGKIN LYMPHOMA UNFIT FOR INTENSIVE THERAPY
    Bender, J.
    Rubinstein, J.
    Pommert, L.
    LEUKEMIA RESEARCH, 2022, 121 : S63 - S64
  • [36] Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
    Piro, LD
    White, CA
    Grillo-López, AJ
    Janakiraman, N
    Saven, A
    Beck, TM
    Varns, C
    Shuey, S
    Czuczman, M
    Lynch, JW
    Kolitz, JE
    Jain, V
    ANNALS OF ONCOLOGY, 1999, 10 (06) : 655 - 661
  • [37] Novel CD20 Mutations As a Mechanism of Resistance to CD20-CD3 Targeted Therapies in Non-Hodgkin's Lymphoma
    Maximov, Victor
    Bolen, Christopher R.
    Polson, Andrew G.
    Penuel, Elicia
    Lasater, Elisabeth A.
    BLOOD, 2023, 142
  • [38] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Gui, Lin
    Han, Xiaohong
    He, Xiaohui
    Song, Yuanyuan
    Yao, Jiarui
    Yang, Jianliang
    Liu, Peng
    Qin, Yan
    Zhang, Shuxiang
    Zhang, Weijing
    Gai, Wenlin
    Xie, Liangzhi
    Shi, Yuankai
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (02) : 197 - 208
  • [39] Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma
    Lin Gui
    Xiaohong Han
    Xiaohui He
    Yuanyuan Song
    Jiarui Yao
    Jianliang Yang
    Peng Liu
    Yan Qin
    Shuxiang Zhang
    Weijing Zhang
    Wenlin Gai
    Liangzhi Xie
    Yuankai Shi
    Chinese Journal of Cancer Research, 2016, (02) : 197 - 208
  • [40] Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
    Repetto-Llamazares, Ada H. V.
    Larsen, Roy H.
    Patzke, Sebastian
    Fleten, Karianne G.
    Didierlaurent, David
    Pichard, Alexandre
    Pouget, Jean Pierre
    Dahle, Jostein
    PLOS ONE, 2015, 10 (06):
12345